Prospective Exploratory Study of a Multiomic Blood Biomarker Panel to Predict Chemotherapy-Induced Peripheral Neuropathy (CIPN)

Inclusion Criteria: * Patients who have received detailed information about the study and have signed, with the investigator, a consent form to participate in the study * Patients being treated for cancer at any stage of the disease and scheduled to receive chemotherapy including one (and only one) of the following molecules: paclitaxel, docetaxel, or oxaliplatin, for a planned duration of 9 weeks or more * Age \> 18 years * Life expectancy \> 3 months * Patient affiliated with or entitled to social security Exclusion Criteria: * Patients already suffering from neuropathy or chronic neurogenic pain * Patients with type 1 or type 2 diabetes (for more than 10 years for type 2 diabetes) * Patients who have already received neurotoxic cancer treatment including those in clinical trials * Patients receiving two of the study molecules simultaneously (only one study molecule is permitted, including in combination chemotherapy but that does not include another neurotoxic molecule) * Patients receiving immunotherapy